5Allanore, Y. and C. Meune (2009). N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis[J]. Clin Exp Rheumatol, 27(3 Suppl 54): 59-63.
6Michowitz Y. Arbel Y. Wexler D, et al. Predictive value of high sensitivity CRP in patients with diastolic heart failure[J]. Int J Cardiol ,2008, 125(3): 347-351.
7Selvais PL, Donckier JE, RobertA, et al. Cardiac natriuretic peptides for diagnosis and risk stratifi'cation in heart failure: influencesof left ventricular dysfunction and coronary artery disease on cardiachormonal activation [J]. Eur J Clin Invest, 1998, 28 ( 8 ) : 636-642.
8Konstantino Y,Kusniec J,ReshefT, et al. Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CI-IF patients[J]. Clin Cardiol, 2007,30(8): 408-413.
9Numaguchi Y, Murohara T. RAAS and angiogenesis [J]. Nippon Rinsho, 2009, 67(4): 723-728.
10Selvais PL, Donckier JE, Robert A, et al.Cardiac natriuretic petides for diagnosis and risk stratification in heartfailure:influences of left ventricular dysfunction and coronary artery disease on cardiac hor- monal activation[J].Eur J Clin Invest, 1998,28(8):636.
4Watanabe H, Kajimoto K, Kawana M. Combination therapy with PDE 111 inhibitor for heart failure[J]. Nihon Rinsho,2007, 65(5) :134- 139.
5Delaney A, Bradford C, MeCaffrey J, et al. Levosimendan for the treatment of acute severe heart failure : a meta - analyses of ran- domized controlled trials [J ]. Int J Cardiol, 2010, 138 (3) : 281 - 289.
